Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab long-term extension in Crohn's disease
NL-OMON54068Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Clinical remission by CDAI at Week 52 and Endoscopic response at Week 52. Started Oct 2020; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON54068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54068.